Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Low Dose of Targeted Agent May Enhance Cancer-Destroying Virus Treatment

By BiotechDaily International staff writers
Posted on 22 Jun 2014
Print article
Administering low doses of the targeted agent bortezomib with a cancer-killing virus has the potential of enhancing the effectiveness of the virus as treatment for cancer with little added toxicity. This, according to researchers from the Ohio State University Comprehensive Cancer Center (Columbus, USA)-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James). These new findings support the testing of this combination therapy in a clinical trial.

Viruses that are devised to destroy cancer cells—oncolytic viruses—have demonstrated potential in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal research suggests that mixing low doses of the drug bortezomib with a specific oncolytic virus might substantially enhance the capacity of the virus to kill cancer cells during therapy.

The research was published online May 9, 2014, in the journal Clinical Cancer Research. “These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity,” said lead investigator Balveen Kaur, PhD, professor and vice chair of research, department of neurological surgery and radiation oncology, and a member of the OSUCCC-James Translational Therapeutics Program. “Because bortezomib is already approved by the [US] Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination.”

Bortezomib suppressed the activity of proteasomes, structures in cells that break down and recycle proteins. Prof. Kaur noted that blocking these “cellular recycling plants” triggers a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, the investigators used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include: (1) One of the overexpressed heat-shock proteins, HSP90, facilitates oncolytic virus replication, enabling the virus to kill more tumor cells; (2) in a glioma model, the combined treatment suppressed tumor growth by 92% in relation to controls and improved survival (six of eight tumors had entirely regressed by day 23 after treatment); (3) lastly, similar outcomes occurred in a head and neck cancer model.

“To our knowledge, this study is the first to show synergy between an oncolytic HSV-1-derived cancer killing virus and bortezomib,” Prof. Kaur concluded. “It offers a novel therapeutic strategy that can be rapidly translated in patients with various solid tumors.”

Related Links:

Ohio State University Comprehensive Cancer Center



Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Drug Discovery

view channel
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).

First High-Throughput Imaging Platform for Predicting Kidney Toxicity of Chemicals

Researchers have developed a high-throughput platform of automated cellular imaging that efficiently and accurately predicts renal toxicity of chemical compounds without animal testing, providing an improved... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.